You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity
|
|---|---|
| Published in |
JAMA Oncology, June 2019
|
| DOI | 10.1001/jamaoncol.2018.6634 |
| Pubmed ID | |
| Authors |
Elizabeth A. M. Feijen, Wendy M. Leisenring, Kayla L. Stratton, Kirsten K. Ness, Helena J. H. van der Pal, Elvira C. van Dalen, Gregory T. Armstrong, Gregory J. Aune, Daniel M. Green, Melissa M. Hudson, Jacqueline Loonen, Kevin C. Oeffinger, Leslie L. Robison, Yutaka Yasui, Leontien C. M. Kremer, Eric J. Chow |
X Demographics
The data shown below were collected from the profiles of 46 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 15 | 33% |
| Spain | 3 | 7% |
| Mexico | 3 | 7% |
| Japan | 2 | 4% |
| Saudi Arabia | 2 | 4% |
| United Kingdom | 2 | 4% |
| Brazil | 1 | 2% |
| Singapore | 1 | 2% |
| Colombia | 1 | 2% |
| Other | 6 | 13% |
| Unknown | 10 | 22% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 26 | 57% |
| Practitioners (doctors, other healthcare professionals) | 11 | 24% |
| Scientists | 7 | 15% |
| Science communicators (journalists, bloggers, editors) | 2 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 108 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 108 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 11 | 10% |
| Other | 9 | 8% |
| Student > Ph. D. Student | 9 | 8% |
| Researcher | 9 | 8% |
| Student > Master | 7 | 6% |
| Other | 24 | 22% |
| Unknown | 39 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 35 | 32% |
| Biochemistry, Genetics and Molecular Biology | 11 | 10% |
| Unspecified | 4 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 4% |
| Agricultural and Biological Sciences | 3 | 3% |
| Other | 8 | 7% |
| Unknown | 43 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 112. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 February 2024.
All research outputs
#379,070
of 26,017,215 outputs
Outputs from JAMA Oncology
#619
of 3,345 outputs
Outputs of similar age
#7,855
of 371,367 outputs
Outputs of similar age from JAMA Oncology
#26
of 101 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,345 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 84.3. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 371,367 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 101 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.